CAL
SUPN icon

Capital Advisors Ltd’s Supernus Pharmaceuticals SUPN Stock Holding History

Capital Advisors Ltd’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8K Hold
173
– – ﹤0.01% 898
2026
Q1 		$9K Hold
173
– – ﹤0.01% 856
2025
Q4 		$9K Hold
173
– – ﹤0.01% 841
2025
Q3 		$8K Buy
173
+21
+14% +$846 ﹤0.01% 852
2025
Q2 		$5K Buy
152
+147
+2,940% +$4.71K ﹤0.01% 934
2025
Q1 		$0 Hold
5
– – ﹤0.01% 1568
2024
Q4 		$0 Hold
5
– – ﹤0.01% 1570
2024
Q3 		$0 Hold
5
– – ﹤0.01% 1601
2024
Q2 		$0 Hold
5
– – ﹤0.01% 1626
2024
Q1 		$0 Hold
5
– – ﹤0.01% 1537
2023
Q4 		$0 Buy
+5
New +$133 ﹤0.01% 1475

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Capital Advisors Ltd's SUPN Position: Q2 2026 in Review

Capital Advisors Ltd held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 173 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #898.

Capital Advisors Ltd first reported a position in SUPN in Q4 2023 and has held it in 11 quarters since. The position peaked at $9K in Q1 2026. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Capital Advisors Ltd held 173 shares of Supernus Pharmaceuticals worth $8K as of Q2 2026.
  • Capital Advisors Ltd left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #898 holding.
  • Capital Advisors Ltd first reported a position in Supernus Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Capital Advisors Ltd's Supernus Pharmaceuticals position peaked at $9K in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.